Why a Supplement Label Is Not Proof
Pick up a supplement bottle and the label reads like a credential: exact doses, percentage signs, precise ingredient names. Under United States law, very little of that has been checked by anyone outside the company that sold it. This page explains the 1994 statute behind the arrangement — what manufacturers must establish before a product reaches a shelf, what they never have to establish, and how to read a label once you know the difference.
What the evidence supports
- The Dietary Supplement Health and Education Act of 1994 classifies supplements as a subcategory of food: no FDA pre-market approval of safety or effectiveness is required.
- The enforcement burden runs backward — the FDA must assemble evidence that a product presents a significant or unreasonable risk before it can act, which took a decade for ephedra.
- Later backstops are real but late: manufacturing rules (2007) and mandatory reporting of serious adverse events (2006) arrived years after the framework did.
What remains uncertain
- How often labels match contents across the whole market — sampling studies disagree sharply depending on whether they read DNA or chemistry.
- Whether the new-ingredient notification pathway screens anything meaningful: government audits document filings that never happen.
- Even the size of the market is an estimate; no complete registry of products on sale exists.
Evidence last reviewed: September 18, 2026. Conclusions may change as new research is published.
a claim, not a credential
The 1994 Bargain
The Dietary Supplement Health and Education Act — DSHEA — was signed in October 1994, and its central move was a classification decision: dietary supplements would be regulated as a subcategory of food, not as drugs. That single line rewrote who does the proving. A drug maker must persuade the FDA with trial data before a product is sold; a supplement maker sells first and answers questions later, if the agency ever asks. The Supplement Safety topic covers the full quality ledger; this page stays on the legal framework everything else hangs from.
- 🏛️ Food, not drugs — supplements skip pre-market approval entirely; there is no FDA sign-off before a bottle reaches a shelf.
- ⚖️ Burden reversed — the company does not have to show safety; the government has to show a significant or unreasonable risk before it can act.
- 🆕 One narrow exception — ingredients not marketed in the US before October 15, 1994 count as "new" and require a pre-market safety notification; audits have repeatedly found this requirement widely ignored (GAO, 2009).
- 📈 The scale of it — roughly half of US adults report using at least one supplement (NHANES data; Bailey et al., 2013).
What the Label Legally Means
A supplement label is a legal document with required parts: the Supplement Facts panel (identity and quantity per serving, percent of Daily Value where one exists), other ingredients in descending order, and a responsible company's name and address. Since 2007, manufacturers must also follow Current Good Manufacturing Practice rules covering identity, purity, strength, and composition.
Here is the part the typography hides in plain sight: every one of those statements is self-made. The company declares what is in the bottle; the agency audits a fraction of facilities and tests a fraction of products, mostly after complaints. An ingredient list is a promise written in the first person — not a measurement anyone outside the company performed on the bottle you are holding. A 2006 law added one honest anchor — serious adverse events must be reported to the FDA within 15 business days — but reporting on harm is not prevention of it.
What No One Has to Show You
Effectiveness is where the gap is widest: a manufacturer never has to demonstrate, to anyone, that a supplement does what it suggests. What the law allows instead is the structure-function claim — "supports immune health," "helps maintain joint comfort," "promotes energy" — with two strings attached. The claim must not name a disease (that would make the product an unapproved drug), and the label must carry the disclaimer saying the FDA has not evaluated the claim.
Read that disclaimer the way a lawyer would: it is the manufacturer telling you, in small print required by Congress, that no regulator checked the sentence on the front. Words like "supports" and "promotes" are not findings; they are legal artifacts that promise too little to be held to anything. The box is the more informative half of the label.
What Must Be Established Before Sale
The cleanest way to see the framework is to set it beside the one prescription drugs face — same shelf, opposite legal machinery.
| Before sale, who checks… | Prescription drugs | Supplements under DSHEA | The gap |
|---|---|---|---|
| 🆔 Identity & potency | Validated assays, batch-by-batch release testing | The company's own GMP paperwork | Self-attested |
| 🛡️ Safety | Clinical trials plus FDA review of the evidence | Not required pre-market for ingredients sold before 1994 | No gate |
| 📈 Effectiveness | Phase 3 trials against placebo | Never required, by anyone | Never asked |
| ✅ FDA pre-market review | Formal application required before marketing | None — the agency typically learns of a product after launch | Reversed |
| 🚨 Adverse-event reporting | Required, continuous, with active surveillance | Serious events reportable since 2006 — after the sale | After the fact |
The Backstop Runs Backward
Because the burden sits with the agency, removing a dangerous product means building a case against a company that had to build none. Ephedra is the canonical demonstration. The FDA's final rule banning ephedra took effect in 2004 — about a decade after the harm signals started arriving. The other backstops arrived on similarly unhurried schedules, which is the point of the chart below: everything resembling a guardrail came years to decades after the framework did.
Verification Is Not Benefit
One distinction does more work on this topic than any other: product verification and evidence of benefit are different questions answered by different methods, and a label can satisfy one while saying nothing about the other. Product verification — a USP or NSF mark — means an independent lab checked that the bottle contains what the label says, at the stated potency, without listed contaminants. That is a claim about the bottle. Evidence of benefit asks whether the substance inside does anything for people like you — a question answered by trials in humans, not by assays of a pill.
The two axes are regularly conflated, and the conflation runs both ways. A verified bottle of an ineffective substance is compliant and useless; an unverified bottle of a well-studied substance may deliver real effects at unknown dose. The third-party certification page takes the verification axis deeper; for benefit, the big-five supplements and longevity supplement candidates pages hold this site's evidence reviews. Never let a purity seal stand in for a trial.
Reading the Back Panel Like an Auditor
None of this means supplements are a minefield; it means the label is where your diligence starts, not where the manufacturer's ended:
- 🔍 Look for a third-party mark — USP, NSF, or an equivalent verification program; it raises confidence the contents match the label — a claim about identity, not benefit.
- 🧮 Do the serving arithmetic — doses are listed per serving, and servings are not per capsule; the multiplication step is where "1,000 mg" quietly becomes three softgels — the dose and stacking page works the arithmetic.
- 🧾 Treat blends as what they are — a "proprietary blend" lists ingredients without amounts, legal because amounts were never a requirement.
- 🏷️ Classify the claim — "supports," "promotes," and "helps maintain" mark structure-function claims no one pre-checked; treat them as advertising copy with a legal pedigree.
- 🩺 Reconcile everything, quarterly — supplements interact with medications and each other; the quarterly audit protocol owns the medication-reconciliation checklist.
Watch-Items and Honest Limits
- 🩸 Liver flags after a new product — new jaundice, dark urine, right-upper-abdomen pain, or unusual fatigue within weeks of starting something new routes to a clinician promptly.
- 🫀 Stimulant-pattern flags — palpitations, chest pain, or blood-pressure spikes after products marketed for energy, weight loss, or performance: stop and seek care; the red-flags page maps the list.
- 📊 Surveys flatter supplement users — takers are healthier than non-takers largely because they were healthier to start; that association is not causation.
- 🗂️ Regulators work from estimates — without a product registry, lab tests and category sweeps sample slivers of the market.
⚠️ When a bottle becomes a clinician visit
The framework on this page is slow by design — post-market, complaint-driven. So the fast part is you: new jaundice, a rash with fever, palpitations, or a lab value that moves after a new product goes to a clinician first and the supplement drawer second. Serious reactions can be reported to the FDA through its Safety Reporting Portal, and medication reconciliation belongs to the quarterly audit protocol, not memory.
The Bottom Line
- The label is a claim, not a credential — since 1994, supplements are regulated as food: no pre-market demonstration of safety or effectiveness, and the Supplement Facts panel is the manufacturer describing itself.
- The burden of proof runs backward — regulators must assemble evidence of significant risk to remove a product, which took about a decade even for ephedra.
- Verification is not benefit — third-party seals establish that the bottle matches the label; whether the contents help anyone is a question only human trials answer. Keep the axes separate on every purchase.
- Audit what you buy, and know the exits — serving arithmetic, blend transparency, claim class, quarterly medication reconciliation; liver, cardiac, or rash red flags after a new product route to a clinician.
Related Topics
- Dietary Supplement Health and Education Act of 1994, Public Law 103-417 (1994)
- Dietary Supplement and Nonprescription Drug Consumer Protection Act, Public Law 109-462 (2006)
- U.S. Food and Drug Administration, "Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements," Final Rule (2007)
- Haller C.A., Benowitz N.L., "Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids," New England Journal of Medicine (2000)
- Shekelle P.G., et al., "Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis," JAMA (2003)
- Bailey R.L., Gahche J.J., Miller P.E., Thomas P.R., Dwyer J.T., "Why US adults use dietary supplements," JAMA Internal Medicine (2013)
- U.S. Government Accountability Office, "Dietary Supplements: FDA Should Take Further Actions to Improve Oversight and Safety," GAO-09-250 (2009)